Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E. coli Nissle 1917 in Grass Pollen Allergy
NCT01013259Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2009
- Primary completion
- Sep 2009
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of escherichia coli nissle 1917 in allergic rhinoconjunctivitis (ARC), sponsored by Charité – Universitätsmedizin Berlin. Started Feb 2009; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01013259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013259.